AngioDynamics Soars 12.67% on Strong Q4 Earnings

On July 15, 2025, AngioDynamics' stock surged by 12.67% in pre-market trading, reflecting a significant boost in investor confidence.

AngioDynamics concluded its fiscal Q4 2025 with robust financial performance, reporting net sales of $80.2 million, marking a 12.7% year-over-year increase and surpassing analyst projections. This strong performance was driven by a 22% growth in its medical technology segment, which contributed to a free cash flow of $16.2 million and positive adjusted EBITDA. The company also expanded its market opportunity to $10 billion, indicating a promising outlook for future growth.

The company's earnings report for Q4 2025 further highlighted its financial strength, with a non-GAAP EPS of -$0.03, exceeding estimates by $0.09. Revenue grew by 12.9% year-over-year, underscoring the company's ability to deliver consistent growth and meet market expectations.